AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 241 min read$AKTS

Czibere Akos sold $259K of AKTS

Czibere Akos (Chief Medical Officer) sold 12,500 shares of Aktis Oncology, Inc. (AKTS) at an average of $20.69 ($20.19–$21.03, $0.26M total) across 2 trades on 2026-09-23 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Czibere Akos
Published Sep 24, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AKTS
Bearish
medium confidence
Mentioned
$AKTS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AKTSBearishLow
01

Why it matters

Provides fresh data on insider holdings, useful for short-term sentiment assessment.

02

Market read

First public disclosure of a senior insider's complete exit from AKTS shares.

03

What to watch

Potential upcoming clinical milestones may offset sell pressure.

Relevance 3/10Novelty 4/10Timing: filed after market close on Sep 24

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$AKTSBearishMedium confidence
Context

Chief Medical Officer sold 12,500 shares for $258,621 via a 10b5-1 plan, leaving zero holdings.

Expected impact

Potential modest dip in short-term price as market digests insider sell.

Evidence & confidence

Sale size is modest relative to market cap, but complete exit by a senior officer is noteworthy.

Market effects

Sector

Minimal impact on biotech sector; typical insider sell.

Regional

No broader regional effect.

Global

Limited to AKTS investors.

Counterpoint

What could challenge this read

The sale could be routine liquidity management, not a negative signal.

Key entities

  • Person
    Czibere Akos

    Chief Medical Officer of Aktis Oncology, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AKTS insider trading history →

Related articles

OCT 1
$AKTSMedAI 8/10

Aktis Oncology initiates phase 1b trial for lung cancer drug

Aktis Oncology (NASDAQ:AKTS) began a Phase 1b trial for AKY-2519 in lung cancer and other solid tumors. The multicenter study will test three dose levels. The company also has ongoing trials for prostate cancer and Nectin-4 expressing tumors, with data expected in 2027. Aktis develops targeted radioconjugates and collaborates with Eli Lilly.

investing.com2 min
AUG 13
$AKTSMed

Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026

Aktis Oncology, Inc. (AKTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 • Presented first-in-human clinical imaging and dosimetry data for AKY-2519, supporting a broad clinical development program in patients with prostate, lung, and other B7-H3 expressing so

SEC EDGAR 8-K6 min
OCT 23
$RENTMed

Nexus Capital Management LP (Cohen Michael S, Flesh Daniel E.) purchased $2.2M of RENT (indirect holdings)

Nexus Capital Management LP purchased 632,922 indirectly-held shares of Rent the Runway, Inc. (RENT) at $3.55 ($2.25M total) on 2026-10-21. Filed jointly with Gateway Runway, LLC (Director), Gateway Runway Intermediate Holdings, Inc. (Director), NEXUS SPECIAL SITUATIONS III, L.P. (Director), NEXUS SPECIAL SITUATIONS III (CAYMAN), L.P. (Director), Nexus Special Situations GP III, LP (Director), Nexus Partners III, LLC (Director), Cohen Michael S (Director), Flesh Daniel E. (Director) and Giangiacomo Damian (Director).

SEC EDGAR1 min
OCT 22
$DOLELow

Pale Fire Capital SE (Senkypl Dusan, Barta Jan) purchased $8.6M of DOLE (indirect holdings)

Pale Fire Capital SE purchased 648,356 indirectly-held shares of Dole plc (DOLE) at an average of $13.19 ($13.12–$13.39, $8.55M total) across 3 trades over 2026-10-20 to 2026-10-22. Filed jointly with Pale Fire Capital SICAV a.s. (10% owner), Pale Fire Capital investicni spolecnost a.s. (10% owner), Senkypl Dusan (10% owner) and Barta Jan (10% owner).

SEC EDGAR1 min